Final results of a phase I study of cabozantinib (cabo) plus nivolumab (nivo) and cabonivo plus ipilimumab (Ipi) in patients (pts) with metastatic urothelial carcinoma (mUC) and other genitourinary (GU) malignancies

被引：0
|
作者：
Nadal, R. [1 ]
Mortazavi, A. [2 ]
Stein, M. [3 ]
Pal, S. K. [4 ]
Davarpanah, N. [1 ]
Parnes, H. L. [1 ]
Ning, Y. M. [1 ]
Cordes, L. M. [1 ]
Lin, J. [1 ]
Bagheri, M. [5 ]
Linderberg, L. [1 ]
Berniger, M. [1 ]
Steinberg, S. M. [6 ]
Moore, T. [4 ]
Lancaster, T. [2 ]
Aviles, M. [3 ]
Costello, R. [1 ]
Bottaro, D. P. [1 ]
Dahut, W. L. [1 ]
Apolo, A. B. [1 ]
机构：
[1] NCI, Med Oncol, Ctr Canc Res, Bethesda, MD 20892 USA
[2] Ohio State Univ, Internal Med, James Canc Hosp, Columbus, OH 43210 USA
[3] Canc Inst New Jersey, Div Med Oncol, New Brunswick, NJ USA
[4] City Hope Natl Med Ctr, Med Oncol, Duarte, CA USA
[5] NCI, Ctr Canc Res, Radiol & Imaging Sci, Bethesda, MD 20892 USA
[6] NCI, Ctr Canc Res, Biostat & Data Management Sect, Bethesda, MD 20892 USA
来源：
ANNALS OF ONCOLOGY | 2017年 / 28卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
846O
引用
收藏
页数：1
相关论文
共 50 条
  • [41] The influence of body composition on the survival of patients with metastatic clear cell renal carcinoma (mccRCC) treated with nivolumab (nivo) plus ipilimumab (ipi).
    Grewal, Kabir
    Chauhan, Pankaj Kumar
    Mukhida, Sagar S.
    Tannir, Nizar M.
    Venkatesh, Neha
    Shah, Amishi Yogesh
    Zurita, Amado J.
    Johns, Andrew
    Campbell, Matthew T.
    Goswami, Sangeeta
    Gao, Jianjun
    Jonasch, Eric
    Mcquade, Jennifer Leigh
    Alhalabi, Omar
    Msaouel, Pavlos
    Hahn, Andrew Warren
    JOURNAL OF CLINICAL ONCOLOGY, 2025, 43 (5_SUPPL) : 545 - 545
  • [42] Nivolumab (NIVO) plus ipilimumab (IPI) combination therapy in patients (pts) with advanced hepatocellular carcinoma (aHCC): Subgroup analyses from CheckMate 040
    He, Aiwu Ruth
    Yau, Thomas
    Hsu, Chiun
    Kang, Yoon-Koo
    Kim, Tae-You
    Santoro, Armando
    Sangro, Bruno
    Melero, Ignacio
    Kudo, Masatoshi
    Hou, Ming-Mo
    Matilla, Ana
    Tovoli, Francesco
    Knox, Jennifer J.
    El-Rayes, Bassel F.
    Acosta-Rivera, Mirelis
    Neely, Jaclyn
    Shen, Yun
    Tschaika, Marina
    El-Khoueiry, Anthony B.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (04)
  • [43] Phase I/II study of ipilimumab plus nivolumab combined with sacituzumab govitecan in patients with metastatic cisplatin-ineligible urothelial carcinoma
    Jain, R. K.
    Chatwal, M.
    Chadha, J.
    Oschmann, E.
    Mizelle, S.
    Poehlman, T.
    Fan, W.
    Kim, Y.
    Dhillon, J.
    Wang, X.
    Zhang, J.
    Guevara, J-A.
    Sonpavde, G. P.
    ANNALS OF ONCOLOGY, 2024, 35 : S1141 - S1141
  • [44] Updated results from a phase I study of nivolumab (Nivo) in combination with ipilimumab (Ipi) in metastatic renal cell carcinoma (mRCC): The CheckMate 016 study
    Hammers, H.
    Plimack, E. R.
    Infante, J. R.
    Rini, B. I.
    McDermott, D.
    Lewis, L.
    Voss, M. H.
    Sharma, P.
    Pal, S. K.
    Razak, A.
    Kollmannsberger, C. K.
    Heng, D.
    Spratlin, J.
    McHenry, B.
    Gagnier, P.
    Amin, A.
    ANNALS OF ONCOLOGY, 2016, 27
  • [45] Nivolumab (NIVO) plus ipilimumab (IPI) combination therapy in patients (Pts) with advanced hepatocellular carcinoma (aHCC): Long-term results from CheckMate 040.
    El-Khoueiry, Anthony B.
    Yau, Thomas
    Kang, Yoon-Koo
    Kim, Tae-You
    Santoro, Armando
    Sangro, Bruno
    Melero, Ignacio
    Kudo, Masatoshi
    Hou Ming-Mo
    Matilla, Ana
    Tovoli, Francesco
    Knox, Jennifer J.
    He, Aiwu Ruth
    El-Rayes, Bassel F.
    Acosta-Rivera, Mirelis
    Lim, Ho Yeong
    Memaj, Arteid
    Sama, Ashwin Reddy
    Hsu, Chiun
    JOURNAL OF CLINICAL ONCOLOGY, 2021, 39 (03)
  • [46] A phase I clinical trial on intratumoural (IT) administration of ipilimumab (IPI) plus nivolumab (NIVO) followed by intracavitary (IC) administration of nivolumab in patients with recurrent glioblastoma
    Schwarze, J. K.
    Bertels, C.
    Awada, G.
    Tijtgat, J.
    Tuyaerts, S.
    Cras, L.
    Vaeyens, F.
    Vanbinst, A-M.
    Everaert, H.
    Michotte, A.
    Caljon, B.
    Olsen, C.
    Janssen, T.
    Van Dooren, S.
    Forsyth, R.
    Duerinck, J.
    Neyns, B.
    ANNALS OF ONCOLOGY, 2020, 31 : S1443 - S1443
  • [47] A phase I trial to assess the biologic effect of CBM588 (Clostridium butyricum) in combination with nivolumab plus ipilimumab (nivo/ipi) in patients with metastatic renal cell carcinoma (mRCC)
    Bergerot, Paulo Gustavo
    Dizman, Nazli
    Ruel, Nora
    Frankel, Paul Henry
    Hsu, Joann
    Pal, Sumanta K.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [48] A pilot randomized study evaluating nivolumab (nivo) or nivo plus bevacizumab (bev) or nivo plus ipilimumab (ipi) in patients with metastatic renal cell carcinoma (MRCC) eligible for cytoreductive nephrectomy, metastasectomy or post-treatment biopsy (Bx).
    Gao, Jianjun
    Karam, Jose A.
    Tannir, Nizar M.
    Campbell, Matthew T.
    Tidwell, Rebecca Slack
    Ahrar, Kamran
    Rao, Priya
    Ng, Chaan S.
    Jonasch, Eric
    Matin, Surena F.
    Zurita, Amado J.
    Shah, Amishi Yogesh
    Shen, Yu
    Blando, Jorge M.
    Vence, Luis M.
    Basu, Sreyashi
    Zhao, Hao
    Allison, James Patrick
    Wood, Christopher G.
    Sharma, Padmanee
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [49] Phase I/II study of ipilimumab plus nivolumab combined with sacituzumab govitecan in patients with metastatic cisplatin-ineligible urothelial carcinoma.
    Jain, Rohit K.
    Yang, Yuanquan
    Chadha, Juskaran
    Chatwal, Monica Sheila
    Kish, Julie Ann
    Raymond, Sarah
    Rembisz, Jennifer
    Jameel, Ghazal
    Mustasam, Arfa
    Poehlman, Trey
    Fan, Wenyi
    Kim, Youngchul
    Dhillon, Jasreman
    Alemany, Carlos A.
    Mortazavi, Amir
    Zhang, Jingsong
    Sonpavde, Guru P.
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41
  • [50] A randomized phase Ib/II study of niraparib (nira) plus nivolumab (nivo) or ipilimumab (ipi) in patients (pts) with platinum-sensitive advanced pancreatic cancer (aPDAC).
    Reiss, Kim Anna
    Mick, Rosemarie
    Teitelbaum, Ursina R.
    O'Hara, Mark H.
    Schneider, Charles John
    Massa, Ryan Campbell
    Karasic, Thomas Benjamin
    Onyiah, Chioma
    Gosselin, Mary Kate
    Donze, Alyssa
    Domchek, Susan M.
    Vonderheide, Robert H.
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
12345